Literature DB >> 677121

Hemorrhagic death associated with a high titer factor V inhibitor.

M C Coots, A F Muhleman, H I Glueck.   

Abstract

An acquired bleeding diathesis was first noted in a 51-year-old patient 11 days following an exploratory laparotomy. Laboratory studies indicated the cause of bleeding to be the development of a circulating anticoagulant which inhibited factor V activity. The inhibitor, an immunoglobulin of the IgG class, was separated by use of Sephadex G-200 filtration, disc electrophoresis, and isoelectric focusing. Despite vigorous immunosuppressive, antifibrinolytic, and replacement therapy, including the use of a "prothrombin complex" and plasmaphoresis, the bleeding diathesis could not be reversed and the patient died of hemorrhage. Although inhibitors to factor V are not usually associated with major life-threatening hemorrhage, this case demonstrates that the development of such an inhibitor can be an ominous finding. The use of an aminoglycoside antibiotic in this and other patients so reported may be one of the contributing causes to the development of such an inhibitor.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 677121     DOI: 10.1002/ajh.2830040212

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

Review 1.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

2.  Human coagulation factor Va is a cofactor for the activation of protein C.

Authors:  H H Salem; G J Broze; J P Miletich; P W Majerus
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

3.  Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity.

Authors:  T L Ortel; M A Quinn-Allen; L A Charles; D Devore-Carter; W H Kane
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

4.  Isolation and study of an acquired inhibitor of human coagulation factor V.

Authors:  M E Nesheim; W L Nichols; T L Cole; J G Houston; R B Schenk; K G Mann; E J Bowie
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

5.  Coagulation factor Va binds to human umbilical vein endothelial cells and accelerates protein C activation.

Authors:  I Maruyama; H H Salem; P W Majerus
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

6.  Rapid elimination of a high-titer spontaneous factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression.

Authors:  B Tribl; P Knöbl; K Derfler; S Kapiotis; G Aspöck; U Jäger; W Hörl; K Lechner
Journal:  Ann Hematol       Date:  1995-10       Impact factor: 3.673

7.  Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets.

Authors:  J P Miletich; D W Majerus; P W Majerus
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

8.  Biosynthesis of coagulation Factor V by a human hepatocellular carcinoma cell line.

Authors:  D B Wilson; H H Salem; J S Mruk; I Maruyama; P W Majerus
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.